Discovery of new erbB4 inhibitors: Repositioning an orphan chemical library by inverse virtual screening.

Inverse Virtual Screening (IVS) is a docking based approach aimed to the evaluation of the virtual ability of a single compound to interact with a library of proteins. For the first time, we applied this methodology to a library of synthetic compounds, which proved to be inactive towards the target they were initially designed for. Trifluoromethyl-benzenesulfonamides 3-21 were repositioned by means of IVS identifying new lead compounds (14-16, 19 and 20) for the inhibition of erbB4 in the low micromolar range. Among these, compound 20 exhibited an interesting value of IC50 on MCF7 cell lines, thus validating IVS in lead repurposing.

[1]  G. Bifulco,et al.  Inhibition of Wnt/β-Catenin pathway and Histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer , 2017, Scientific Reports.

[2]  Ashutosh Kumar,et al.  A pose prediction approach based on ligand 3D shape similarity , 2016, Journal of Computer-Aided Molecular Design.

[3]  G. Bifulco,et al.  Discovery and synthesis of namalide reveals a new anabaenopeptin scaffold and peptidase inhibitor. , 2012, Journal of medicinal chemistry.

[4]  Edgar R. Wood,et al.  6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases , 2008, Proceedings of the National Academy of Sciences.

[5]  M. Washington,et al.  ERBB4 is over-expressed in human colon cancer and enhances cellular transformation. , 2015, Carcinogenesis.

[6]  G. Bifulco,et al.  Discovery of new potent molecular entities able to inhibit mPGES-1. , 2018, European journal of medicinal chemistry.

[7]  K. Lackey,et al.  The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. , 2001, Molecular cancer therapeutics.

[8]  J. Baselga,et al.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 , 2009, Nature Reviews Cancer.

[9]  M F Sanner,et al.  Python: a programming language for software integration and development. , 1999, Journal of molecular graphics & modelling.

[10]  G. Bifulco,et al.  Inverse Virtual Screening allows the discovery of the biological activity of natural compounds. , 2012, Bioorganic & medicinal chemistry.

[11]  G. Bifulco,et al.  Structural evidence of N6-isopentenyladenosine as a new ligand of farnesyl pyrophosphate synthase. , 2014, Journal of medicinal chemistry.

[12]  A. Bender,et al.  In silico target fishing: Predicting biological targets from chemical structure , 2006 .

[13]  W. C. Still,et al.  Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .

[14]  R. Rosell,et al.  Other targeted drugs in melanoma. , 2015, Annals of translational medicine.

[15]  G. Bifulco,et al.  New steroids with a rearranged skeleton as (h)P300 inhibitors from the sponge Theonella swinhoei. , 2014, Organic letters.

[16]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis , 2009, PLoS Comput. Biol..

[17]  Jennifer L. Knight,et al.  OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. , 2016, Journal of chemical theory and computation.

[18]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[19]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[20]  O. Navarro,et al.  Recent Developments in the Suzuki-Miyaura Reaction: 2010–2014 , 2015, Molecules.

[21]  Petra Schneider,et al.  Identifying the macromolecular targets of de novo-designed chemical entities through self-organizing map consensus , 2014, Proceedings of the National Academy of Sciences.

[22]  Sergey Plis,et al.  Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data. , 2016, Molecular pharmaceutics.

[23]  G. Bifulco,et al.  Structural basis for the design and synthesis of selective HDAC inhibitors. , 2013, Bioorganic & medicinal chemistry.

[24]  Gianluigi Lauro,et al.  Inverse virtual screening of antitumor targets: pilot study on a small database of natural bioactive compounds. , 2011, Journal of natural products.

[25]  Claudio N. Cavasotto,et al.  Ligand docking and structure-based virtual screening in drug discovery. , 2007, Current topics in medicinal chemistry.

[26]  Gisbert Schneider,et al.  A Computational Method for Unveiling the Target Promiscuity of Pharmacologically Active Compounds. , 2017, Angewandte Chemie.

[27]  J. Settleman.  A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin. , 2009, Cancer cell.

[28]  Woody Sherman,et al.  Rapid Shape-Based Ligand Alignment and Virtual Screening Method Based on Atom/Feature-Pair Similarities and Volume Overlap Scoring , 2011, J. Chem. Inf. Model..

[29]  Meir Glick,et al.  Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..

[30]  J. Medina-Franco,et al.  Toward Drug Repurposing in Epigenetics: Olsalazine as a Hypomethylating Compound Active in a Cellular Context , 2014, ChemMedChem.

[31]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[32]  G. Bifulco,et al.  Structural insights into Estrogen Related Receptor-β modulation: 4-Methylenesterols from Theonella swinhoei sponge as the first example of marine natural antagonists , 2014, Steroids.

[33]  Jimmy Lin,et al.  Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4 , 2009, Nature Genetics.

[34]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[35]  Y.Z. Chen,et al.  Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.

[36]  Dik-Lung Ma,et al.  Drug repositioning by structure-based virtual screening. , 2013, Chemical Society reviews.